Literature DB >> 35964800

Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer.

Shruti Gupta1, Ian A Strohbehn2, Qiyu Wang2, Paul E Hanna2, Rituvanthikaa Seethapathy2, Jason M Prosek3, Sandra M Herrmann4, Ala Abudayyeh5, A Bilal Malik6, Sebastian Loew7, Christopher A Carlos8, Wei-Ting Chang9, Pazit Beckerman10, Zain Mithani11, Chintan V Shah12, Amanda D Renaghan13, Sophie de Seigneux14, Luca Campedel15, Abhijat Kitchlu16, Daniel Sanghoon Shin17, Gaia Coppock18, Nuttha Lumlertgul19, Pablo Garcia20, David I Ortiz-Melo21, Arash Rashidi22, Ben Sprangers23, Vikram Aggarwal24, Karolina Benesova25, Kenar D Jhaveri26, Frank B Cortazar27, Astrid Weins28, Yiqin Zuo29, Meghan J Mooradian30, Kerry L Reynolds30, David E Leaf1, Meghan E Sise31.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35964800      PMCID: PMC9523226          DOI: 10.1016/j.kint.2022.07.019

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   18.998


× No keyword cloud information.
  9 in total

1.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC.

Authors:  Daphne W Dumoulin; Sabine Visser; Robin Cornelissen; Teun van Gelder; Johan Vansteenkiste; Jan von der Thusen; Joachim G J V Aerts
Journal:  J Thorac Oncol       Date:  2020-04-30       Impact factor: 15.609

3.  Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study.

Authors:  Sabine Visser; Jeannine Huisbrink; Nils E van 't Veer; Jermo J van Toor; Anton J M van Boxem; Nico C van Walree; Bruno H Stricker; Joachim G J V Aerts
Journal:  Eur Respir J       Date:  2018-10-25       Impact factor: 16.671

4.  Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin.

Authors:  Shveta S Motwani; Gearoid M McMahon; Benjamin D Humphreys; Ann H Partridge; Sushrut S Waikar; Gary C Curhan
Journal:  J Clin Oncol       Date:  2018-01-10       Impact factor: 44.544

5.  Kidney tubular toxicity of maintenance pemetrexed therapy.

Authors:  Ilya G Glezerman; M Catherine Pietanza; Vincent Miller; Surya V Seshan
Journal:  Am J Kidney Dis       Date:  2011-08-17       Impact factor: 8.860

6.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

7.  Acute kidney injury in patients treated with immune checkpoint inhibitors.

Authors:  Shruti Gupta; Samuel A P Short; Meghan E Sise; Jason M Prosek; Sethu M Madhavan; Maria Jose Soler; Marlies Ostermann; Sandra M Herrmann; Ala Abudayyeh; Shuchi Anand; Ilya Glezerman; Shveta S Motwani; Naoka Murakami; Rimda Wanchoo; David I Ortiz-Melo; Arash Rashidi; Ben Sprangers; Vikram Aggarwal; A Bilal Malik; Sebastian Loew; Christopher A Carlos; Wei-Ting Chang; Pazit Beckerman; Zain Mithani; Chintan V Shah; Amanda D Renaghan; Sophie De Seigneux; Luca Campedel; Abhijat Kitchlu; Daniel Sanghoon Shin; Sunil Rangarajan; Priya Deshpande; Gaia Coppock; Mark Eijgelsheim; Harish Seethapathy; Meghan D Lee; Ian A Strohbehn; Dwight H Owen; Marium Husain; Clara Garcia-Carro; Sheila Bermejo; Nuttha Lumlertgul; Nina Seylanova; Lucy Flanders; Busra Isik; Omar Mamlouk; Jamie S Lin; Pablo Garcia; Aydin Kaghazchi; Yuriy Khanin; Sheru K Kansal; Els Wauters; Sunandana Chandra; Kai M Schmidt-Ott; Raymond K Hsu; Maria C Tio; Suraj Sarvode Mothi; Harkarandeep Singh; Deborah Schrag; Kenar D Jhaveri; Kerry L Reynolds; Frank B Cortazar; David E Leaf
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

8.  Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.

Authors:  Frank B Cortazar; Zoe A Kibbelaar; Ilya G Glezerman; Ala Abudayyeh; Omar Mamlouk; Shveta S Motwani; Naoka Murakami; Sandra M Herrmann; Sandhya Manohar; Anushree C Shirali; Abhijat Kitchlu; Shayan Shirazian; Amer Assal; Anitha Vijayan; Amanda DeMauro Renaghan; David I Ortiz-Melo; Sunil Rangarajan; A Bilal Malik; Jonathan J Hogan; Alex R Dinh; Daniel Sanghoon Shin; Kristen A Marrone; Zain Mithani; Douglas B Johnson; Afrooz Hosseini; Deekchha Uprety; Shreyak Sharma; Shruti Gupta; Kerry L Reynolds; Meghan E Sise; David E Leaf
Journal:  J Am Soc Nephrol       Date:  2020-01-02       Impact factor: 10.121

9.  Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis.

Authors:  Kang Liu; Zhongke Qin; Xueqiang Xu; Ting Li; Yifei Ge; Huijuan Mao; Changying Xing
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.